INS and primary biliary cholangitis: TUDCA is also being used in a phase 2 clinical trial for treating juvenile diabetes (NCT02218619), has been shown to improve insulin sensitivity in obese people30 and could be used for treating primary biliary cirrhosis or PBC31.